| 李新飞,林乐涛,宋莉,邹英华.肝细胞癌的靶向免疫治疗及其在介入领域的应用[J].中国介入影像与治疗学,2018,15(8):501-505 |
| 肝细胞癌的靶向免疫治疗及其在介入领域的应用 |
| Targeted therapy of immunotherapy in hepatocellular carcinoma and its application in interventional field |
| 投稿时间：2018-03-23 修订日期：2018-05-29 |
| DOI：10.13929/j.1672-8475.201803043 |
| 中文关键词: 癌,肝细胞 靶向治疗 抗血管生成药 免疫治疗 化学栓塞,治疗性 |
| 英文关键词:Carcinoma,hepatocellular Targeted therapy Anti-angiogenic drug Immunotherapy Chemoembolization,therapeutic |
| 基金项目: |
|
| 摘要点击次数: 2479 |
| 全文下载次数: 1034 |
| 中文摘要: |
| 根治性治疗只适用于部分肝细胞癌（HCC）患者，多数中晚期患者常需要接受其他治疗，现有方法远不能满足肝癌患者的需求。除索拉菲尼外的抗血管生成药可作为二线药物治疗HCC。动物实验或临床试验已初步证实了程序性细胞死亡分子-1抗体、DC-细胞因子诱导的杀伤细胞（CIK）和嵌合抗原受体（CAR-T）技术治疗HCC的疗效，且靶向免疫治疗联合介入疗法可能获得更佳疗效。本文对HCC的靶向免疫治疗及其在介入领域的应用进展进行综述。 |
| 英文摘要: |
| Radical treatment of hepatocellular carcinoma (HCC) only applies to part of patients. The majority of patients with advanced HCC usually need to receive other treatments, the existing therapies are far from meeting the needs. Anti-angiogenic drugs other than sorafenib can be used as second-line drugs. The efficacy of programmed death-1 antibody, DC-cytokine induced kill cell and chimeric antigen receptor-T technology has been proven in animal experiments or clinical trials. Anti-angiogenic drugs or immunotherapy combined with interventional therapy may enable patients to obtain better efficacy. The progresses of targeted immunotherapy of HCC and its interventional applications were reviewed in this article. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
